Although the use of immunotherapy has revolutionized the treatment of non-small-cell lung cancer, patterns of immunostaining with PD-L1, a biomarker for treatment response, may vary in tumor cells across individual primary tumors (e.g., (,) cases E and F) [22]. The gene discussed is CD274; the disease is neoplasm.